MX2021000609A - Métodos de tratamiento con fármacos sustrato para cyp3a4. - Google Patents
Métodos de tratamiento con fármacos sustrato para cyp3a4.Info
- Publication number
- MX2021000609A MX2021000609A MX2021000609A MX2021000609A MX2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A
- Authority
- MX
- Mexico
- Prior art keywords
- cyp3a4 substrate
- treatment
- methods
- patient
- substrate drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente descripción proporciona métodos para tratar a un paciente con un fármaco sustrato para CYP3A4, en donde se trata al paciente con posaconazol. En algunas modalidades, el paciente suspende el tratamiento con posaconazol, espera durante al menos 2 días y después se trata con el fármaco sustrato para CYP3A4 tan pronto como sea seguro hacerlo. En algunas modalidades, el tratamiento con el fármaco sustrato para CYP3A4 se retrasa durante aproximadamente 2-42 días después de suspender el posaconazol. En algunas modalidades, se trata al paciente con una dosis reducida del fármaco sustrato para CYP3A4 durante aproximadamente 2-42 días.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/596,585 US10376507B2 (en) | 2017-05-16 | 2017-05-16 | Method of treating a patient with a CYP3A4 substrate drug |
US16/036,678 US20180333411A1 (en) | 2017-05-16 | 2018-07-16 | Methods of treatment |
PCT/US2018/061141 WO2020018136A1 (en) | 2017-05-16 | 2018-11-14 | Methods of treatment with cyp3a4 substrate drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000609A true MX2021000609A (es) | 2021-06-23 |
Family
ID=64269934
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019013714A MX2019013714A (es) | 2017-05-16 | 2017-05-16 | Metodos de tratamiento. |
MX2021000609A MX2021000609A (es) | 2017-05-16 | 2018-11-14 | Métodos de tratamiento con fármacos sustrato para cyp3a4. |
MX2022013410A MX2022013410A (es) | 2017-05-16 | 2019-11-15 | Metodos de tratamiento. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019013714A MX2019013714A (es) | 2017-05-16 | 2017-05-16 | Metodos de tratamiento. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013410A MX2022013410A (es) | 2017-05-16 | 2019-11-15 | Metodos de tratamiento. |
Country Status (14)
Country | Link |
---|---|
US (4) | US10376507B2 (es) |
EP (3) | EP4082546A1 (es) |
JP (6) | JP2020520380A (es) |
KR (3) | KR20210010663A (es) |
AU (10) | AU2017414697B2 (es) |
CA (2) | CA3062770A1 (es) |
DK (1) | DK3426250T3 (es) |
ES (1) | ES2912373T3 (es) |
HR (1) | HRP20220536T1 (es) |
MX (3) | MX2019013714A (es) |
PL (1) | PL3426250T3 (es) |
SI (1) | SI3426250T1 (es) |
WO (2) | WO2018212764A1 (es) |
ZA (1) | ZA202006746B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3394057T1 (sl) | 2015-12-23 | 2022-06-30 | Neurocrine Biosciences, Inc. | Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
SG11201906883SA (en) | 2017-01-27 | 2019-08-27 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
PL3426250T3 (pl) * | 2017-05-16 | 2022-08-08 | Bow River LLC | Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4 |
US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
US10835529B2 (en) | 2017-05-16 | 2020-11-17 | Bow River LLC | Methods of treatment with CYP3A4 substrate drugs |
US20220143011A1 (en) | 2017-05-16 | 2022-05-12 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
US11110098B2 (en) * | 2017-06-07 | 2021-09-07 | University Of Kansas | Methods and medicaments for the treatment of renal cell carcinoma |
WO2019060322A2 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
EP3980072A4 (en) * | 2019-06-05 | 2023-06-14 | University of Georgia Research Foundation | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION RELATED TO HUMAN IMMUNE DEFICIENCY VIRUS |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
JP2023506768A (ja) | 2019-12-12 | 2023-02-20 | ティン セラピューティックス エルエルシー | 聴覚損失の予防及び治療のための組成物及び方法 |
AU2021412785A1 (en) * | 2020-12-31 | 2023-06-22 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
US11229644B1 (en) | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
CN112675175B (zh) * | 2021-02-01 | 2022-11-01 | 天津济坤医药科技有限公司 | 布里格替尼在制备治疗特发性肺纤维化的药物中的应用 |
WO2023101441A1 (ko) * | 2021-11-30 | 2023-06-08 | 에스케이케미칼 주식회사 | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 |
WO2023141634A2 (en) * | 2022-01-24 | 2023-07-27 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
CN117257994B (zh) * | 2023-11-21 | 2024-03-01 | 北京大学人民医院 | 动物模型的构建方法及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973970B2 (en) * | 2000-08-09 | 2011-07-05 | Ether Visuals Llc | Preventing artifacts that may be produced when bottling PDL files converted from raster images |
WO2007140299A2 (en) | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals |
US7820681B1 (en) * | 2009-01-14 | 2010-10-26 | Mutual Pharmaceutical Company, Inc. | Methods for concomitant administration of colchicine and a second active agent |
US7816383B1 (en) * | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
US11304902B2 (en) | 2014-11-25 | 2022-04-19 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
US10493024B2 (en) | 2015-10-12 | 2019-12-03 | Hk Tumescent Pharma Corporation | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
KR20190067918A (ko) | 2016-11-09 | 2019-06-17 | 사인패스 파마 인코포레이티드 | 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과 |
PL3426250T3 (pl) | 2017-05-16 | 2022-08-08 | Bow River LLC | Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4 |
US10835529B2 (en) | 2017-05-16 | 2020-11-17 | Bow River LLC | Methods of treatment with CYP3A4 substrate drugs |
-
2017
- 2017-05-16 PL PL17897227.9T patent/PL3426250T3/pl unknown
- 2017-05-16 SI SI201731136T patent/SI3426250T1/sl unknown
- 2017-05-16 EP EP22163202.9A patent/EP4082546A1/en active Pending
- 2017-05-16 ES ES17897227T patent/ES2912373T3/es active Active
- 2017-05-16 CA CA3062770A patent/CA3062770A1/en active Pending
- 2017-05-16 WO PCT/US2017/032924 patent/WO2018212764A1/en active Application Filing
- 2017-05-16 HR HRP20220536TT patent/HRP20220536T1/hr unknown
- 2017-05-16 KR KR1020217001925A patent/KR20210010663A/ko not_active Application Discontinuation
- 2017-05-16 JP JP2019572833A patent/JP2020520380A/ja active Pending
- 2017-05-16 KR KR1020197036786A patent/KR20200010320A/ko active Application Filing
- 2017-05-16 EP EP17897227.9A patent/EP3426250B1/en active Active
- 2017-05-16 AU AU2017414697A patent/AU2017414697B2/en active Active
- 2017-05-16 MX MX2019013714A patent/MX2019013714A/es unknown
- 2017-05-16 DK DK17897227.9T patent/DK3426250T3/da active
- 2017-05-16 US US15/596,585 patent/US10376507B2/en active Active
- 2017-08-07 US US15/670,271 patent/US20180333410A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/036,678 patent/US20180333411A1/en not_active Abandoned
- 2018-11-14 MX MX2021000609A patent/MX2021000609A/es unknown
- 2018-11-14 EP EP18926463.3A patent/EP3716976A4/en active Pending
- 2018-11-14 AU AU2018432858A patent/AU2018432858A1/en active Pending
- 2018-11-14 JP JP2020536002A patent/JP6984024B2/ja active Active
- 2018-11-14 CA CA3103793A patent/CA3103793A1/en active Pending
- 2018-11-14 KR KR1020217004371A patent/KR20210045400A/ko not_active Application Discontinuation
- 2018-11-14 WO PCT/US2018/061141 patent/WO2020018136A1/en unknown
-
2019
- 2019-03-12 US US16/351,198 patent/US20190255043A1/en not_active Abandoned
- 2019-11-15 MX MX2022013410A patent/MX2022013410A/es unknown
-
2020
- 2020-03-24 AU AU2020202100A patent/AU2020202100B2/en active Active
- 2020-03-30 AU AU2020202266A patent/AU2020202266B2/en active Active
- 2020-06-02 AU AU2020203606A patent/AU2020203606B2/en active Active
- 2020-06-02 AU AU2020203608A patent/AU2020203608B2/en active Active
- 2020-06-02 AU AU2020203607A patent/AU2020203607B2/en active Active
- 2020-10-08 AU AU2020250281A patent/AU2020250281B2/en active Active
- 2020-10-29 ZA ZA2020/06746A patent/ZA202006746B/en unknown
-
2021
- 2021-01-21 JP JP2021008114A patent/JP2021059610A/ja active Pending
- 2021-11-24 JP JP2021189815A patent/JP7353343B2/ja active Active
-
2022
- 2022-07-05 AU AU2022204806A patent/AU2022204806A1/en active Pending
- 2022-09-08 AU AU2022228153A patent/AU2022228153A1/en active Pending
- 2022-12-12 JP JP2022198263A patent/JP2023021260A/ja active Pending
-
2023
- 2023-09-19 JP JP2023150724A patent/JP2023174661A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000609A (es) | Métodos de tratamiento con fármacos sustrato para cyp3a4. | |
MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
NZ755166A (en) | Biofilm disrupting composition for use on chronic wounds | |
MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
AR086051A1 (es) | Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit | |
NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
NZ735952A (en) | Dosing regimen for missed doses for long-acting injectable paliperidone esters | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
WO2019126695A3 (en) | Methods and pharmaceutical compositions for treating candida auris in blood | |
RU2011120773A (ru) | Способ лечения вторичной лактазной недостаточности | |
MX2023006765A (es) | Metodo para proporcionar terapia de celiprolol a un paciente. | |
UA116484U (uk) | Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом | |
SG10201700775YA (en) | A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease | |
UA125566U (uk) | Спосіб лікування хворих на феліноз | |
PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
UA109492C2 (uk) | Спосіб відновлювального лікування хворих на псоріаз | |
UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті | |
UA116487C2 (uk) | Спосіб лікування гнійно-запальних процесів протимікробними засобами | |
UA115711U (xx) | Спосіб лікування печінкової енцефалопатії у хворих з вторинним біліарним цирозом печінки | |
MD854Z (ro) | Metodă de tratament al cancerului cervical local avansat de stadiul II-III |